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Background: Colorectal cancer (CRC) screening programs using fecal immuno-
chemical test (FIT) have to choose a cut- off value to decide which citizens to recall 
for colonoscopy. The evidence on the optimal cut- off value is sparse and based on 
studies with a low number of cancer cases.
Methods: This observational study used data from the Danish Colorectal Cancer 
Screening Database. Sensitivity and specificity were estimated for various cut- off 
values based on a large number of cancers. Traditionally optimal cut- off values are 
found by weighting sensitivity and specificity equally. As this might result in too 
many unnecessary colonoscopies we also provide optimal cut- off values for different 
weighting of sensitivity and specificity/number of needed colonoscopies to detect one 
cancer.
Results: Weighting sensitivity and specificity equally gives an optimal cut- off value 
of 45 ng Hb/ml. This, however, means making 24 colonoscopies to detect one cancer. 
Weighting sensitivity lower and for example, aiming at making about 16 colonosco-
pies to detect one cancer, gives an optimal cut- off value of 125 ng Hb/ml.
Conclusions: The optimal cut- off value in an FIT population- based screening pro-
gram is 45 ng Hb/ml, when as traditionally sensitivity and specificity are weighted 
equally. If, however, 24 colonoscopies needed to detect one cancer is too huge a 
burden on the health care system and the participants, 80, 125, 175, and 350 ng Hb/
ml are optimal cut- off values when only 19/16/14/10 colonoscopies are accepted to 
find one cancer.
K E Y W O R D S
capacity building, colorectal neoplasms, mass screening, sensitivity, specificity
1 |  INTRODUCTION
In order to detect colorectal cancer (CRC) at a precancer-
ous or early stage, where it is curable, several countries 
and regions have started population- based CRC screening. 
Different methods/technologies are used to screen people for 
CRC. Since colorectal adenomas and tumors often bleed,1 
one possible screening method is the fecal immunochemical 
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test (FIT), which detects tiny amounts of human hemoglobin 
in a stool sample.
Screening should sort out apparently healthy persons who 
probably have a disease from those who probably do not.2 
In FIT screening the sorting is done by allocating partici-
pants with an FIT level above a certain cut- off value (positive 
screening test) to the group who probably have CRC, leaving 
those with an FIT level below a certain cut- off value (nega-
tive screening test) in the group who probably do not have 
CRC.
The cut- off value should be chosen so that the odds of 
having a positive screening test given that you have the dis-
ease (sensitivity) is as high as possible, while at the same 
time maximizing the odds of having a negative screening 
test given that you do not have the disease (specificity). 
Decreasing the cut- off value to get a higher sensitivity will 
though inevitably decrease specificity. The optimal cut- off 
value, therefore, depends upon how important an increase in 
sensitivity is weighted compared to the inevitable following 
decrease in specificity.
Six studies have previously reported sensitivity and 
specificity for various cut- off values.3- 8 However, all of 
these studies are based on a low number of CRCs and 
none of the studies are from population- based screening 
programs.
This register- based study aims at estimating sensitivity 
and specificity for various cut- off values in the prevalence 
round of a population- based FIT screening program with a 
large number of CRCs, and thereby provide optimal cut- off 
values for various weighting of sensitivity and specificity.
2 |  METHODS
2.1 | The Danish CRC screening program
Population- based CRC screening with FIT started in 
Denmark in March 2014 for citizens aged 50– 74  years. 
In order to gradually build up the needed capacity in hos-
pitals, the first screening round took almost 4  years and 
ended in December 2017. All citizens aged 50– 74  years 
at some point in 2014– 2017 were invited to participate 
in the first screening round.9 Citizens already enrolled in 
a surveillance program after a CRC or adenoma diagno-
sis, were advised in the invitation letter not to participate. 
Citizens with inflammatory bowel disease were advised to 
discuss with their treating physician whether participation 
was relevant. Returned FITs were analyzed using the OC 
Sensor Diana (2013– 2017) (Eiken Chemical Company), 
yielding how much hemoglobin the sample contains. A 
test was considered positive if the stool- sample contained 
more than 100 ng hemoglobin (Hb)/ml (20 µg Hb/g feces 
as the sample bottle collects 10 mg feces and contains 2 ml 
buffer). Citizens with a positive FIT were informed by let-
ter and referred to colonoscopy at a hospital- based screen-
ing endoscopy unit.
2.2 | Study design and population
Our study population consists of all participants in the Danish 
CRC screening program who submitted an analyzable stool- 
sample between 1 March 2014 and 31 December 2015. The 
study population was followed for CRC diagnoses for 2 years 
after the sample was analyzed.
2.3 | Data
Information on invitation date, date when returned sam-
ple was analyzed and the amount of blood in the sample 
was retrieved from the Danish CRC Screening Database 
(DCCSD),10 a clinical quality database that was established 
to monitor the quality of the national Danish CRC screening 
program. FIT- values below 35 ng Hb/ml were only known 
as ≤35 ng Hb/ml and FIT- values above 1000 ng Hb/ml were 
only known as ≥1000 ng Hb/ml. DCCSD gets individual data 
on all invitations and participation from the administrative 
database IAM.11 Information on CRCs, adenomas, and colo-
noscopies was obtained from the Danish National Pathology 
Data Bank and the Danish National Patient Register. Data 
were linked using the unique Danish personal registration 
number issued to all Danish residents. The completeness and 
reliability of the Danish National Pathology Data Bank and 
the Danish National Patient Register is deemed to be very 
high and good.12,13
Lay Summary
Studies with relatively few cancers have estimated 
the optimal cut- off value in FIT- based CRC screen-
ing to be 50– 150 ng Hb/ml when, as traditionally, 
weighting sensitivity, and specificity equally.
It can be discussed whether it is acceptable to weight 
sensitivity and specificity equally as this results 
in many unnecessary colonoscopies to detect one 
cancer.
No studies have estimated optimal cut- off value 
without weighting sensitivity and specificity equally.
This study used different weighting of sensitivity 
and specificity and found that given it is acceptable 
to make 24/19/16/14/10 colonoscopies to detect one 
cancer, the optimal cut- off value is 45, 80, 125, 175, 
and 350 ng Hb/ml.
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2.4 | Definitions
We identified CRCs as samples from the colon or rectum with 
a SNOMED code M8*3 (cancer). Adenoma(s) were identi-
fied as samples from the colon or rectum with one of these 
SNOMED codes: M8213F (flat adenoma), M82110 (tubular 
adenoma), M82130 (traditional serrated adenoma), M8213M 
(sessile serrated lesion with dysplasia), M82630 (tubulovil-
lous adenoma), and M82611 (villous adenoma).
We defined a participant as a citizen who sent in an ana-
lyzable stool- sample in the study period (1 March 2014 and 
31 December 2015). A positive FIT is a FIT where the mea-
sured amount of blood is above the cut off level. We esti-
mated the number of true positive/false positive FITs by the 
number of positive FITs where the participant is diagnosed/
not diagnosed with CRC 0– 24 months after the test. Similarly 
the number of false negative/true negative FITs was esti-
mated by the number of nonpositive FITs where the partici-
pant is diagnosed/not diagnosed with CRC 0– 24 months after 
the test. We defined Sensitivity for the FIT test as the number 
of true positives divided by the number of true positives plus 
the number of false negatives. Specificity was defined as the 
number of true negatives divided by the number of true neg-
atives plus the number of false positives.
2.5 | Analyses
In order to avoid that the number of cancers within each 
group of FIT values were too low, the span of the analyzed 
cut- off values was 5 ng Hb/ml for cut- off values between 35 
and 75 ng Hb/ml; 10 ng Hb/ml for cut- off values between 80 
and 100 ng Hb/ml; 25 ng Hb/ml for cut- off values between 
100 and 500 ng Hb/ml and 100 ng Hb/ml for cut- off values 
between 500 and 1000 ng Hb/ml.
In the optimal study design all participants would have 
had a subsequent colonoscopy. This was, however, not the 
case in this observational study. As many of the cancers 
are at an early stage when discovered by screening it is 
not likely that all true positive cases with a cut- off value 
between 100 ng Hb/ml and 100 + x ng Hb/ml would have 
emerged as cancers in 2 years after the test, had the cut- 
off value been 100 + x ng Hb/ml. As we estimate number 
of false negative cases by number of negative test, which 
emerges as cancer in 2 years after the test, we did not know 
how many false negative cases there would have been, had 
the cut- off value been above 100  ng Hb/ml. We neither 
know how many true positive cases there would have been, 
had the cut- off value been below 100 ng Hb/ml, as these 
participants had no colonoscopy. There are 18.04 true pos-
itive cases per 1000 tests among tests with a cut- off value 
of 100– 149 ng Hb/ml, whereas there are 6.35 false negative 
cases per 1000 tests among tests with a cut- off value of 
80– 99 ng Hb/ml. Close to 100 ng Hb/ml the ratio between 
number of true positive cases and number of false negative 
cases is, therefore, approximately 2.8 (18.04/6.35). In our 
main analysis, we assumed that the ratio between number 
of true positive cases and number of false negative cases 
was 2.8 for all cut- off values. The ratio between the num-
ber of true positive cases and the number of false negative 
cases might though be lower for high FIT values than for 
low FIT values. We, therefore, made two sensitivity analy-
ses, one assuming the ratio to decrease linearly (dotted line, 
Figure 1) and one assuming the ratio to follow a hyperbola 
(dashed line, Figure 1).
A receiver operating characteristic curve (ROC curve) 
was used to show the trade- off between sensitivity and 
specificity.14 The Youden index, that is, sensitivity + spec-
ificity, is a commonly used measure of overall diagnostic 
effectiveness.15 Traditionally the optimal cut- off point is 
F I G U R E  1  The assumed ratio between 
number of true positive cases and number 
of false negative cases for cut- off values 
0– 1000 ng Hb/ml
assuming the ratio decreases linearly 
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found by putting equal weight on sensitivity and specific-
ity and thereby maximizing sensitivity  +  specificity (the 
Youden index). We not only calculated the optimal cut- off 
value using this method, but also recognized that it might 
not be appropriate in CRC screening to weight sensitivity 
and specificity equally. The current cut- off value (100 ng 
Hb/ml) resulted in 495,785 true negative, 33,496 false 
positive, 2086 true positive and 461 false negative, giving 
a specificity of 93.7% and 81.9% sensitivity. Decreasing 
specificity by 1– 92.7% would result in almost 5000 cancer- 
free citizens referred unnecessarily to colonoscopy (1% 
of about 500,000 participants without cancer). Increasing 
sensitivity by 1– 82.9% would result in 25 extra citizens 
having their cancer detected at screening (1% of about 
2500 participants with cancer). Whether 5000 unneces-
sary colonoscopies (1% change in specificity) should be 
weighted equally to 25 extra cancers detected (1% change 
in sensitivity) is a decision to make in each screening pro-
gram. If the burden of unnecessary colonoscopies on the 
health care system and the participants should be weighted 
higher then specificity should be given more weight than 
sensitivity. We, therefore, also calculated the Youden index 
giving different weighting to specificity versus sensitivity. 
To visualize how these different weighting of sensitivity 
versus specificity affects number of screen- detected CRC 
and number of needed colonoscopies, we for each optimal 
cut- off value also calculated percentage CRCs missed/
detected and percentage less/extra colonoscopies needed 
compared to a cut- off of 100 ng Hb/ml.
The 10- year average risk that an advanced adenoma tran-
sition to CRC has been reported to be 25– 40%.16 Although 
it is important to detect adenomas at CRC screening it is not 
equally important as finding CRCs. It is, therefore, not ap-
propriate to include the number of screen- detected adenomas 
when calculating sensitivity and specificity. To show how the 
number of detected adenomas is affected by choice of cut- off 
value, we calculated percentage missed adenomas compared 
to a cut- off value of 100 ng Hb/ml for each optimal cut- off 
value.
Data were processed using SAS (version 9.4).
3 |  RESULTS
In total 532,316 citizens accepted the invitation to CRC 
screening and sent in a stool sample before 31 December 
2015. Of these 488 only sent in un- analyzable stool samples 
and were, therefore, excluded from the analyses (Figure 2). 
Among the remaining 531,828 eligible participants 35,582 
had a FIT value above 100  ng Hb/ml and were, therefore, 
invited to colonoscopy. Of these 90.1% (32,057) had a colo-
noscopy within 6 months (Figure 2).
At the current cut- off value of 100 ng Hb/ml, screening 
of 531,828 citizens resulted in 2086 screen detected cancers 
(true positive cases), 33,496 false positive cases, 495,785 
true negative cases and 461 interval cancers (false negative 
cases). Table 1 shows that Increasing the cut- off value from 
100 to 200 ng Hb/ml will decrease the sensitivity from 81.9% 
F I G U R E  2  Flowchart of study 
population and exclusions
Citizens participation in CRC
screening 1/1-2014 - 31/12-2015
532,316
Citizens only sending in
un-analysable samples
488
Colonoscopy in 6 months
32,057




FIT value <100 mg Hb/L
496,246
No colonoscopy in 6 months
3525
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[95% CI: 80.8– 83.0%] to 77.0% [95% CI: 75.7– 78.2%] and 
increase the specificity from 93.7% [95% CI: 93.6– 93.7%] to 
95.9% [95% CI: 95.8– 95.9%].
The ROC curve (Figure  3) shows that a cut- off value 
of 45  ng Hb/ml result in a point on the ROC curve 
closest to (0,1), that is, maximizes the Youden index 
(0.873  +  0.898  =  1.771). The present cut- off value of 
100  ng Hb/ml results in a slightly lower Youden index 
(0.819 + 0.937 = 1.756)/further distance to (0,1). Lowering 
the cut- off value to 45 ng Hb/ml will, however, result in 24 
colonoscopies needed to detect one cancer (Table 2). If this 
is considered to be a too high burden on the health care sys-
tem and the participants, sensitivity needs to be weighted 
lower than specificity.
Table  2 shows the optimal cut- off value for different 
weighing of sensitivity and specificity. Weighting sen-
sitivity by 40% and specificity by 60% (i.e., maximizing 
0.4 × sensitivity+0.6 × specificity) and thereby accepting 
to make 19 colonoscopies to detect one cancer gives an 
optimal cut- off value of 80  ng Hb/ml. Using 80  ng Hb/
ml as cut- off value instead of 100  ng Hb/ml will detect 
4% extra cancers at the cost of 13% extra colonoscopies. 
Weighting sensitivity by 35% and specificity by 65% and 
thereby accepting to make 16 colonoscopies to detect one 
cancer gives an optimal cut- off value of 125 ng Hb/ml. The 
effect of using 125  ng Hb/ml as cut- off value instead of 
100 ng Hb/ml is 11% less colonoscopies needed as well as 
8% less adenomas and 3% less cancers detected. As seen in 
Table 2, the two sensitivity analyses resulted in unchanged 
optimal cut- off values except when sensitivity is weighted 
by only 10– 20%.
4 |  DISCUSSION
The study provided optimal cut- off values for FIT- based 
CRC screening for various weighing of sensitivity versus 
specificity. Sensitivity analyses revealed that the provided 
optimal cut- off values were quite robust toward changes to 
the assumptions.
4.1 | Strengths and weaknesses
The major strengths of this study are the large number of par-
ticipants and subsequent cancers as well as the use of high 
validity Danish registers to follow all participants on an indi-
vidual level for 2 years.
We only included cancers diagnosed up to 24 months after 
the FIT to decide whether the test was true positive, false 
positive, false negative or true negative. This can have caused 
some misclassification, for example, citizens with a positive 
FIT and a CRC not found at colonoscopy nor within the next 
2 years, will be falsely categorized as false positive although 
they are true positive. This number is though low, as num-
ber of interval cancers after a clean colon colonoscopy in the 
Danish CRC screening program is low.17 As seen in our sen-
sitivity analyses small changes to number of true/false posi-
tive and true/false negative cases only result in minor changes 
to the optimal cut- off values, wherefore the effect of these 
misclassifications is expected to be minimal.
As only participants with a cut- off value above 100 ng Hb/
ml had a subsequent colonoscopy, we had to estimate num-
ber of false negative cases had the cut- off value been above 
100 ng Hb/ml and number of true positive cases had the cut- 
off value been below 100 ng Hb/ml. Our sensitivity analyses 
though showed that the results are quite robust toward major 
T A B L E  1  Sensitivity and specificity for different cut- off values
Cut- off value Sensitivity Specificity
40 89.5% [88.7– 90.3%] 82.7% [82.6– 82.8%]
45 87.3% [86.4– 88.2%] 89.8% [89.7– 89.8%]
50 86.5% [85.6– 87.4%] 90.4% [90.3– 90.4%]
55 85.9% [84.9– 86.9%] 90.9% [90.8– 90.9%]
60 85.5% [84.5– 86.5%] 91.3% [91.2– 91.3%]
65 84.8% [83.8– 85.8%] 91.7% [91.7– 91.8%]
70 84.0% [83.0– 85.1%] 92.1% [92.1– 92.2%]
75 83.8% [82.7– 84.8%] 92.5% [92.5– 92.6%]
80 83.4% [82.4– 84.5%] 92.8% [92.7– 92.8%]
90 82.6% [81.5– 83.7%] 93.3% [93.2– 93.3%]
100 81.9% [80.8– 83.0%] 93.7% [93.6– 93.7%]
125 80.7% [79.5– 81.8%] 94.4% [94.3– 94.4%]
150 79.5% [78.3– 80.7%] 94.9% [94.9– 95.0%]
175 78.4% [77.2– 79.6%] 95.4% [95.4– 95.5%]
200 77.0% [75.7– 78.2%] 95.9% [95.8– 95.9%]
225 75.5% [74.2– 76.8%] 96.2% [96.2– 96.3%]
250 74.4% [73.0– 75.7%] 96.5% [96.5– 96.5%]
275 73.5% [72.1– 74.8%] 96.7% [96.7– 96.8%]
300 72.7% [71.3– 74.0%] 96.9% [96.9– 97.0%]
325 71.8% [70.3– 73.2%] 97.1% [97.1– 97.1%]
350 71.0% [69.5– 72.4%] 97.3% [97.2– 97.3%]
375 70.1% [68.6– 71.5%] 97.4% [97.4– 97.4%]
400 69.4% [67.9– 70.9%] 97.5% [97.5– 97.6%]
425 68.5% [67.0– 70.0%] 97.6% [97.6– 97.7%]
450 67.5% [66.0– 69.0%] 97.7% [97.7– 97.8%]
475 66.8% [65.3– 68.4%] 97.8% [97.8– 97.8%]
500 65.9% [64.3– 67.5%] 97.9% [97.9– 97.9%]
600 63.3% [61.7– 64.9%] 98.2% [98.1– 98.2%]
700 60.8% [59.1– 62.4%] 98.4% [98.3– 98.4%]
800 58.6% [56.9– 60.2%] 98.5% [98.5– 98.5%]
900 57.1% [55.4– 58.8%] 98.6% [98.6– 98.6%]
1000 55.8% [54.1– 57.5%] 98.7% [98.7– 98.7%]
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changes to our assumptions on the ratio between number of 
true positive cases and number of false negative cases.
4.2 | Other studies
Previously six studies have reported on sensitivity and speci-
ficity for various cut- off values.3- 8 The numbers of cancers 
were quite low in all five studies, ranging from 8 to 89 can-
cers. In comparison our study included 2251 cancers.
Weighting sensitivity and specificity equally, Itoh et al., 
Launoy et al., and de Wijkerslooth et al. found an optimal 
cut off value of 50 ng Hb/ml.3- 5 Brenner et al. like us found 
the optimal cut off value to be 45 ng Hb/ml.8 The study by 
Wijkerslooth used the same test as we did (OC- Sensor; Eiken 
Chemical Company), while the other studies used the OC- 
hermodia test (Eiken Chemical Company), the Magstream 
1000 test (Fujirebio Inc.), or the FOB- Gold test (Sentinel 
Diagnostics). Using the OC- Sensor test (Eiken Chemical 
Company) and weighting sensitivity and specificity equally 
Chen et al. found the optimal cut off value, to be 100 ng Hb/
ml and Aniwan et al. found the optimal cut off value to be 
150 ng Hb/ml.6,7 Chen et al. favored a cut off value of 100 ng 
Hb/ml above 50  ng Hb/ml as their study had no cancers 
F I G U R E  3  ROC curve for various cut- 
off values of FIT












values in ng 
Hb/mlc 
Number needed 













50 50 45 45 24 NA 14– 17 extra 59 extra
45 55 60 60 21 NA 9– 10 extra 36 extra
40 60 80 80 19 NA 4 extra 13 extra
35 65 125 125 16 8 3 missed 11 less
30 70 150 150 15 16 6 missed 19 less
25 75 175 175 14 22 8 missed 26 less
20 80 275 200 11/13d 41/28d 19/12d missed 47/33d less
15 85 350 300 10/11d 49/44d 23/20d missed 55/50d less
10 90 475 400 9/10d 57/53d 30/26d missed 63/59d less
aAssuming a constant ratio between number of false negative cases and number of true positive cases of 2.8 (solid line, Figure 1). 
bAssuming the ratio between number of false negative cases and number of true positive cases decreases linearly (dotted line, Figure 1). 
cAssuming the ratio between number of false negative cases and number of true positive cases follow a hyperbola (dashed line, Figure 1). 
dWhen using the optimal cut- off values from the “hyperbola” sensitivity analyses. 
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among FITs with an FIT value between 50 and 100 ng Hb/
ml, resulting in unchanged sensitivity for cut off values be-
tween 50 and 100 ng Hb/ml.6 Similarly Aniwan et al. favored 
150 ng Hb/ml over 50 ng Hb/ml as their study had no cancers 
among FITs with an FIT value between 50 and 150 ng Hb/ml, 
resulting in unchanged sensitivity for cut off values between 
50 and 150 ng Hb/ml.7
Our results, when weighting sensitivity and specificity 
equally, are in line with results from all of these studies, 
suggesting that they are generalizable to other types of FIT. 
Brenner et al. calculated sensitivity and specificity both for 
detecting CRC and advanced neoplasms and found the same 
optimal cut- off value.8
To show results based on real- life data from an organized 
CRC screening program, we also included citizens who 
chose not to have the recommended colonoscopy after a FIT 
value ≥100 ng Hb/ml. In the Danish CRC screening program 
about 90% had a colonoscopy after a positive FIT. Programs 
with a lower colonoscopy participation rate might experience 
“Number needed to scope to find one cancer” different from 
those reported here.
Different cut- off values males and females might be an 
appropriate consideration for future studies as, for example, 
the Danish CRC screening program has shown a higher pos-
itivity rate and increased detection of CRC among males as 
compared to females.17,18
5 |  CONCLUSION
The optimal cut- off value in an FIT population- based screen-
ing program is 45 ng Hb/ml when, as traditionally, sensitiv-
ity, and specificity are weighted equally. If, however, 24 
colonoscopies needed to detect one cancer is too huge a bur-
den on the health care system and the participants, 80, 125, 
175, and 350 ng Hb/ml are optimal cut- off values when only 
19/16/14/10 colonoscopies are accepted to find one cancer.
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